According to all this information, CGM devices are considered the standard of care for most subjects with type 1 diabetes (T1D) [8, 25], but also for those individuals with type 2 diabetes that receive intensive treatment with insulin, and even for those with type 2 diabetes that do not achieve the recommended targets despite basal insulin-only regimens or other antidiabetic drugs, or when minimizing hypoglycemic risk is warranted [26–28]. The gene discussed is INS; the disease is type 1 diabetes mellitus.